Mixed
Gsk239512: repair myelin in relapsing and progressive MS
relapsing and progressive MS · Remyelination / oligodendrocyte repair
Controlled trials disagree.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 131
How the verdict was reached
Mixed phase 2 results
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Gsk239512, phase 2 | Phase 2 | 131 | 2013 | Mixed result GSK239512 was associated with positive effect sizes of 0.344 [90% confidence interval (CI) 0.018, 0.671] and 0.243 (90% CI -0.112, 0.598) for adjusted mean changes in the normalised MTR for GdE and Delta-MTR lesions, respectively. Paper abstract | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Status changed from Results pending to Mixed
- Oct 2026First listed as Results pending
Related hypotheses
Assembled by software from public sources.